Tags

Type your tag names separated by a space and hit enter

The treatment of Kaposi's sarcoma: present and future options, a review of the literature.
Eur Rev Med Pharmacol Sci 2019; 23(17):7488-7497ER

Abstract

Kaposi's Sarcoma (KS) is an angiogenic tumor involving skin, mucosa and splanchnic organs. It is caused by Human Herpes Virus 8 (HHV8), when in the presence of other cofactors, such as an immune dysregulation. KS is particularly frequent in HIV-infected individuals. The major goals of treatment are to prevent disease progression, to reduce tumor and edema, to avoid organ compromise, and to relieve psychological stress. The importance and the high cancer risk offered by this co-infection, together with the spread of both these viruses, and the fact that angiogenesis is such an important characteristic of KS led to a lively interest in finding a definitive therapy. Most of the ongoing studies are focused on finding an application of old drugs in KS. Unfortunately, given the number of studies with different targets, it seems we are still far from completely understanding this disease and obtaining a "cure" which could be effective and safe for everyone. Further studies will hopefully offer new and definitive solutions.

Authors+Show Affiliations

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. gnunnari@unime.it.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31539137

Citation

Ceccarelli, M, et al. "The Treatment of Kaposi's Sarcoma: Present and Future Options, a Review of the Literature." European Review for Medical and Pharmacological Sciences, vol. 23, no. 17, 2019, pp. 7488-7497.
Ceccarelli M, Facciolà A, Taibi R, et al. The treatment of Kaposi's sarcoma: present and future options, a review of the literature. Eur Rev Med Pharmacol Sci. 2019;23(17):7488-7497.
Ceccarelli, M., Facciolà, A., Taibi, R., Pellicanò, G. F., Nunnari, G., & Venanzi Rullo, E. (2019). The treatment of Kaposi's sarcoma: present and future options, a review of the literature. European Review for Medical and Pharmacological Sciences, 23(17), pp. 7488-7497. doi:10.26355/eurrev_201909_18860.
Ceccarelli M, et al. The Treatment of Kaposi's Sarcoma: Present and Future Options, a Review of the Literature. Eur Rev Med Pharmacol Sci. 2019;23(17):7488-7497. PubMed PMID: 31539137.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The treatment of Kaposi's sarcoma: present and future options, a review of the literature. AU - Ceccarelli,M, AU - Facciolà,A, AU - Taibi,R, AU - Pellicanò,G F, AU - Nunnari,G, AU - Venanzi Rullo,E, PY - 2019/9/21/entrez SP - 7488 EP - 7497 JF - European review for medical and pharmacological sciences JO - Eur Rev Med Pharmacol Sci VL - 23 IS - 17 N2 - Kaposi's Sarcoma (KS) is an angiogenic tumor involving skin, mucosa and splanchnic organs. It is caused by Human Herpes Virus 8 (HHV8), when in the presence of other cofactors, such as an immune dysregulation. KS is particularly frequent in HIV-infected individuals. The major goals of treatment are to prevent disease progression, to reduce tumor and edema, to avoid organ compromise, and to relieve psychological stress. The importance and the high cancer risk offered by this co-infection, together with the spread of both these viruses, and the fact that angiogenesis is such an important characteristic of KS led to a lively interest in finding a definitive therapy. Most of the ongoing studies are focused on finding an application of old drugs in KS. Unfortunately, given the number of studies with different targets, it seems we are still far from completely understanding this disease and obtaining a "cure" which could be effective and safe for everyone. Further studies will hopefully offer new and definitive solutions. SN - 2284-0729 UR - https://www.unboundmedicine.com/medline/citation/31539137/The_treatment_of_Kaposi's_sarcoma:_present_and_future_options,_a_review_of_the_literature L2 - https://www.europeanreview.org/article/18860 DB - PRIME DP - Unbound Medicine ER -